Core Viewpoint - Multiple A-share pharmaceutical companies have announced their 2025 performance forecasts, with 160 stocks expected to see year-on-year growth in net profit attributable to shareholders, particularly within the CXO sector, which shows robust performance and is anticipated to recover overall due to a more favorable external environment and a rebound in investment and financing [1][7]. Group 1: Company Performance - WuXi AppTec (603259.SH/2359.HK) is expected to lead in performance growth, forecasting a net profit attributable to shareholders of 19.151 billion yuan, with a non-recurring net profit of 13.241 billion yuan, reflecting a year-on-year increase of 32.6%, surpassing historical peaks [1][8]. - The company has raised its full-year revenue guidance twice in 2025, now projecting total revenue of approximately 45.456 billion yuan, a year-on-year increase of about 15.84%, with sustainable business revenue expected to grow by approximately 21.4% [2][9]. Group 2: Business Model and Growth Drivers - The unique value of WuXi AppTec's "integrated, end-to-end" CRDMO business model has significantly contributed to its performance, with over 430,000 compounds delivered in the drug discovery phase and 621 new molecules entering the D&M pipeline in 2025 [2][9]. - The number of small molecule drugs in Phase III and commercialization has increased from 107 to 167 from 2022 to the third quarter of 2025, representing a 56% year-on-year growth, with corresponding revenue growth exceeding 150% [4][11]. Group 3: Shareholder Returns - WuXi AppTec has emphasized sharing its growth with shareholders, having returned nearly 20 billion yuan through cash dividends and share buybacks over seven years, accounting for over 40% of cumulative net profit [6][14]. - Based on a 30% cash dividend policy and the 2025 performance forecast, the cash dividend amount is expected to double year-on-year, enhancing shareholder returns [6][14].

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 45.456 billion in 2025, representing a year-on-year growth of about 15.84% [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders is anticipated to reach approximately RMB 19.151 billion, showing a significant year-on-year growth of about 102.65% [1] Revenue and Profit Growth - The expected revenue growth is driven by the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - The increase in net profit is also attributed to gains from the sale of partial equity in joint ventures and the divestiture of certain business segments [1]